1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Dyskinesia, Medication-Induced in 128 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As an index of terminal serotonin innervation density, we measured radioligand binding to the plasma membrane serotonin transporter (SERT) in levodopa-treated dyskinetic and nondyskinetic subjects, using brain tissue from both rat and monkey models of Parkinson disease as well as parkinsonian patients." | 3.76 | Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. ( Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D, 2010) |
| " During long-term levodopa therapy, patients develop abnormal movements, dyskinesias, the pathophysiological basis of which is poorly understood." | 3.70 | Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. ( Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM, 1999) |
| "Models of Parkinson's disease (PD) can be produced in several non-human primate (NHP) species by applying neurotoxic lesions to the nigrostriatal dopamine pathway." | 2.52 | Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. ( Fox, SH; Johnston, TM, 2015) |
| "One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management." | 2.42 | Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. ( Linazasoro, G, 2004) |
| " Regular dosing with levodopa or apomorphine reliably resulted in peak dose dyskinesia." | 2.38 | The use of thalamotomy in the treatment of levodopa-induced dyskinesia. ( Page, RD, 1992) |
| "This reduction of parkinsonism was not accompanied by an exacerbation of dyskinesia or PLBs." | 1.56 | Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2020) |
| "Six common marmosets developed parkinsonism following administration of MPTP, after which they were treated chronically with L-DOPA to induce stable dyskinesia and PLBs." | 1.48 | Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2018) |
| "Levodopa treatment increased the specific binding of NMDA receptors in the basal ganglia." | 1.42 | Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy. ( Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M, 2015) |
| " This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM." | 1.40 | Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat ( Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L, 2014) |
| "In animal models of Parkinson's disease (PD), the serotonergic (5-hydroxytryptamine, 5-HT) system is thought to play an important pathophysiological role in the development and expression of l-3,4-dihydroxyphenylalanine (l-3,4-dihydroxyphenylalanine-DOPA)-induced dyskinesia (LID)." | 1.40 | Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. ( Bezard, E; Ko, WK; Li, Q, 2014) |
| "L-DOPA-induced dyskinesias (LID)s are abnormal involuntary movements limiting the chronic use of L-DOPA, the main pharmacological treatment of Parkinson's disease (PD)." | 1.39 | Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. ( Di Paolo, T; Morissette, M; Parent, M; Riahi, G; Samadi, P, 2013) |
| " We retrospectively analyzed data from 17 stable HP rhesus monkeys treated long-term with chronic intermittent dosing of levodopa (LD) in an attempt to induce choreoathetoid and dystonic dyskinesias." | 1.37 | Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys. ( Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T, 2011) |
| "Levodopa-induced dyskinesias (LIDs) are abnormal involuntary movements induced by the chronic use of levodopa (l-Dopa) limiting the quality of life of Parkinson's disease (PD) patients." | 1.37 | Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. ( Di Paolo, T; Morissette, M; Parent, M; Riahi, G, 2011) |
| " Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model." | 1.35 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. ( Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C, 2008) |
| "Ropinirole treatment was continued but some animals also received l-dopa BID or four times daily (QID) with and without entacapone or vehicle for a further 16 days." | 1.34 | The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. ( Jackson, MJ; Jenner, P; Olanow, W; Rose, S; Smith, LA; Stockwell, KA; Tayarani-Binazir, K; Zubair, M, 2007) |
| "Nicotine pretreatment reduced peak and total levodopa-induced dyskinesias in levodopa-naive monkeys over an 8-week period, with a decrease in total dyskinesias of about 50%." | 1.34 | Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. ( Cox, H; Di Monte, D; Langston, JW; O'Leary, K; Parameswaran, N; Quik, M, 2007) |
| " These data support the notion that pulsatile stimulation contributes to the development of dyskinesia and suggests that more frequent dosing of L-dopa plus entacapone may be a useful treatment strategy for patients in the early stages of Parkinson's disease." | 1.33 | Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. ( Al-Barghouthy, G; Jackson, MJ; Jenner, P; Kuoppamaki, M; Olanow, W; Rose, S; Smith, LA, 2005) |
| "Long-term treatment of Parkinson's disease with levodopa is compromised by the development of motor complications, including on-off fluctuations and involuntary movements termed dyskinesia." | 1.32 | Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. ( Brotchie, JM; Crossman, AR; Duty, S; Fox, SH; Henry, B, 2003) |
| " Mild and advanced parkinsonism in nonhuman primates can be produced with fixed dosing regimens of MPTP." | 1.31 | D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. ( Goulet, M; Madras, BK, 2000) |
| " Selective adenosine A(2A) receptor antagonists, such as KW-6002, may be one means of reducing the dosage of L-DOPA used in treating Parkinson's disease and are potentially a novel approach to treating the illness both as monotherapy and in combination with dopaminergic drugs." | 1.31 | Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. ( Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA, 2000) |
| " We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0." | 1.30 | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. ( Bédard, PJ; Britton, DR; Grondin, R; Shiosaki, K, 1997) |
| " These results are consistent with previous work highlighting the importance of aberrant amine production in neurological disease and demonstrate that treatments that reduce endogenous melatonin bioavailability can ameliorate experimental PD." | 1.30 | A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. ( Armstrong, SM; Willis, GL, 1999) |
| "Baclofen was also useful in one monkey against a more dystonic form of dyskinesia." | 1.29 | Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. ( Bédard, PJ; Gomez-Mancilla, B, 1993) |
| " Long-term use of madopa developed a peak-dose dyskinesia of the face and the limbs contralateral to the MPTP-treated side." | 1.28 | [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys]. ( Chen, S, 1992) |
| "Choreic movements were always most prevalent at the time of peak effect, whereas dystonia was apparent at the time of peak effect and at "end-of-dose", and was occasionally observed spontaneously." | 1.28 | Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. ( Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ, 1990) |
| " The dose-response curve for NB-355 was shifted to the right such that approximately twice the dopa equivalent dose of NB-355 was required to stimulate locomotor activity to the same level observed for L-DOPA." | 1.28 | NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys. ( Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (7.03) | 18.7374 |
| 1990's | 32 (25.00) | 18.2507 |
| 2000's | 59 (46.09) | 29.6817 |
| 2010's | 21 (16.41) | 24.3611 |
| 2020's | 7 (5.47) | 2.80 |
| Authors | Studies |
|---|---|
| Nuara, SG | 3 |
| Gourdon, JC | 3 |
| Maddaford, S | 1 |
| Huot, P | 4 |
| Morissette, M | 10 |
| Bourque, M | 4 |
| Tremblay, MÈ | 1 |
| Di Paolo, T | 18 |
| Grégoire, L | 12 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Moreau, C | 1 |
| Rolland, AS | 1 |
| Pioli, E | 1 |
| Li, Q | 6 |
| Odou, P | 1 |
| Barthelemy, C | 1 |
| Lannoy, D | 1 |
| Demailly, A | 1 |
| Carta, N | 1 |
| Deramecourt, V | 1 |
| Auger, F | 1 |
| Kuchcinski, G | 1 |
| Laloux, C | 1 |
| Defebvre, L | 1 |
| Bordet, R | 1 |
| Duce, J | 1 |
| Devedjian, JC | 1 |
| Bezard, E | 11 |
| Fisichella, M | 1 |
| Devos, D | 1 |
| Mann, E | 1 |
| Jackson, M | 4 |
| Lincoln, L | 1 |
| Fisher, R | 1 |
| Rose, S | 6 |
| Duty, S | 2 |
| Hamadjida, A | 2 |
| Kwan, C | 2 |
| Frouni, I | 2 |
| Bédard, D | 2 |
| Beaudry, F | 1 |
| Ahn, S | 1 |
| Song, TJ | 1 |
| Park, SU | 1 |
| Jeon, S | 1 |
| Kim, J | 1 |
| Oh, JY | 1 |
| Jang, J | 1 |
| Hong, S | 1 |
| Song, MA | 1 |
| Shin, HS | 1 |
| Jung, YR | 1 |
| Park, HJ | 1 |
| Riahi, G | 2 |
| Samadi, P | 3 |
| Parent, M | 3 |
| Zhang, L | 1 |
| Balan, G | 1 |
| Barreiro, G | 1 |
| Boscoe, BP | 1 |
| Chenard, LK | 1 |
| Cianfrogna, J | 1 |
| Claffey, MM | 1 |
| Chen, L | 2 |
| Coffman, KJ | 1 |
| Drozda, SE | 1 |
| Dunetz, JR | 1 |
| Fonseca, KR | 1 |
| Galatsis, P | 1 |
| Grimwood, S | 1 |
| Lazzaro, JT | 1 |
| Mancuso, JY | 1 |
| Miller, EL | 1 |
| Reese, MR | 1 |
| Rogers, BN | 1 |
| Sakurada, I | 1 |
| Skaddan, M | 1 |
| Smith, DL | 1 |
| Stepan, AF | 1 |
| Trapa, P | 1 |
| Tuttle, JB | 1 |
| Verhoest, PR | 1 |
| Walker, DP | 1 |
| Wright, AS | 1 |
| Zaleska, MM | 1 |
| Zasadny, K | 1 |
| Shaffer, CL | 1 |
| Morin, N | 4 |
| Jourdain, VA | 2 |
| Ko, WK | 1 |
| Johnston, TM | 1 |
| Fox, SH | 8 |
| Ando, K | 1 |
| Inoue, T | 1 |
| Itoh, T | 1 |
| Urs, NM | 1 |
| Bido, S | 1 |
| Peterson, SM | 1 |
| Daigle, TL | 1 |
| Bass, CE | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Zhang, D | 1 |
| McGregor, M | 1 |
| Bordia, T | 1 |
| Perez, XA | 1 |
| McIntosh, JM | 1 |
| Decker, MW | 1 |
| Quik, M | 5 |
| Rajput, A | 1 |
| Rajput, AH | 1 |
| Bagga, P | 1 |
| Crescenzi, R | 1 |
| Krishnamoorthy, G | 1 |
| Verma, G | 1 |
| Nanga, RP | 1 |
| Reddy, D | 1 |
| Greenberg, J | 1 |
| Detre, JA | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| Muñoz, A | 1 |
| Gardoni, F | 1 |
| Marcello, E | 1 |
| Qin, C | 1 |
| Carlsson, T | 1 |
| Kirik, D | 1 |
| Di Luca, M | 1 |
| Björklund, A | 1 |
| Carta, M | 1 |
| Visanji, NP | 2 |
| Johnston, T | 1 |
| Reyes, G | 1 |
| Millan, MJ | 1 |
| Brotchie, JM | 8 |
| Graham, J | 1 |
| Bédard, PJ | 19 |
| Bartoszyk, GD | 1 |
| Yabe, H | 1 |
| Choudhury, ME | 1 |
| Kubo, M | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Nomoto, M | 1 |
| Astradsson, A | 1 |
| Jenkins, BG | 1 |
| Choi, JK | 1 |
| Hallett, PJ | 3 |
| Levesque, MA | 1 |
| McDowell, JS | 1 |
| Brownell, AL | 1 |
| Spealman, RD | 1 |
| Isacson, O | 1 |
| Kim, ST | 1 |
| Son, HJ | 1 |
| Choi, JH | 1 |
| Ji, IJ | 1 |
| Hwang, O | 1 |
| Silverdale, MA | 2 |
| Kobylecki, C | 1 |
| Dunah, AW | 1 |
| Ravenscroft, P | 2 |
| Saiki, H | 1 |
| Hayashi, T | 1 |
| Takahashi, R | 1 |
| Takahashi, J | 1 |
| Rylander, D | 1 |
| O'Sullivan, SS | 1 |
| Dovero, S | 3 |
| Lees, AJ | 1 |
| Descarries, L | 1 |
| Cenci, MA | 1 |
| Lieu, CA | 1 |
| Deogaonkar, M | 1 |
| Bakay, RA | 2 |
| Subramanian, T | 1 |
| Conte-Perales, L | 1 |
| Rico, AJ | 1 |
| Barroso-Chinea, P | 2 |
| Gómez-Bautista, V | 1 |
| Roda, E | 1 |
| Luquin, N | 1 |
| Sierra, S | 1 |
| Lanciego, JL | 2 |
| Hansard, MJ | 3 |
| Smith, LA | 10 |
| Jackson, MJ | 14 |
| Cheetham, SC | 1 |
| Jenner, P | 21 |
| Tel, BC | 1 |
| Braceras, R | 1 |
| Bonhomme, C | 1 |
| Chezaubernard, C | 1 |
| Del Signore, S | 1 |
| Klintenberg, R | 1 |
| Svenningsson, P | 1 |
| Gunne, L | 1 |
| Andrén, PE | 1 |
| Oh, JD | 3 |
| Bibbiani, F | 3 |
| Chase, TN | 6 |
| Henry, B | 3 |
| Hill, M | 1 |
| Crossman, A | 1 |
| Brotchie, J | 1 |
| Kuoppamäki, M | 4 |
| Al-Barghouthy, G | 4 |
| Smith, L | 3 |
| Zeng, BY | 2 |
| Quinn, N | 1 |
| Maratos, EC | 2 |
| Pearce, RK | 7 |
| Cannizzaro, C | 1 |
| Maratos, E | 1 |
| Ferry, S | 1 |
| Mach, U | 1 |
| Stark, H | 1 |
| Leriche, L | 1 |
| Boraud, T | 2 |
| Gross, C | 1 |
| Sokoloff, P | 1 |
| Chassain, C | 1 |
| Eschalier, A | 1 |
| Durif, F | 1 |
| Iravani, MM | 3 |
| Crossman, AR | 6 |
| Schneider, JS | 3 |
| Gonczi, H | 1 |
| Decamp, E | 1 |
| Petzer, JP | 1 |
| Castagnoli, N | 1 |
| Chen, JF | 1 |
| Schwarzschild, MA | 1 |
| Bélanger, N | 2 |
| Hadj Tahar, A | 4 |
| Nevet, A | 1 |
| Morris, G | 1 |
| Saban, G | 1 |
| Fainstein, N | 1 |
| Bergman, H | 1 |
| Linazasoro, G | 1 |
| Olanow, W | 2 |
| Aubert, I | 2 |
| Guigoni, C | 2 |
| Håkansson, K | 1 |
| Barthe, N | 1 |
| Bioulac, BH | 2 |
| Gross, CE | 3 |
| Fisone, G | 1 |
| Bloch, B | 2 |
| Hagan, JJ | 1 |
| Hurley, MJ | 1 |
| Costa, S | 1 |
| Al-Bargouthy, G | 1 |
| Obeso, JA | 2 |
| Ohashi, S | 1 |
| Mori, A | 1 |
| Kurihara, N | 1 |
| Mitsumoto, Y | 1 |
| Nakai, M | 1 |
| Dridi, M | 1 |
| Calon, F | 4 |
| Meltzer, LT | 1 |
| Lang, AE | 2 |
| Tayarani-Binazir, K | 2 |
| Chu, WB | 1 |
| Gomez-Ramirez, J | 1 |
| Johnston, TH | 1 |
| Pires, D | 1 |
| Voon, V | 1 |
| Smith, CP | 1 |
| Collins, MA | 1 |
| Avila, I | 1 |
| Cox, H | 2 |
| Togasaki, DM | 1 |
| Langston, JW | 3 |
| Di Monte, DA | 2 |
| Cao, X | 1 |
| Liang, L | 1 |
| Hadcock, JR | 1 |
| Iredale, PA | 1 |
| Griffith, DA | 1 |
| Menniti, FS | 1 |
| Factor, S | 1 |
| Greenamyre, JT | 1 |
| Papa, SM | 3 |
| Zubair, M | 1 |
| Stockwell, KA | 1 |
| Parameswaran, N | 1 |
| O'Leary, K | 1 |
| Di Monte, D | 2 |
| Rodríguez-Oroz, MC | 1 |
| Blesa, FJ | 1 |
| Alvarez-Erviti, L | 1 |
| Guridi, J | 1 |
| Smith, Y | 1 |
| Nicholas, AP | 1 |
| Lubin, FD | 1 |
| Vattem, P | 1 |
| Zhou, S | 1 |
| Sweatt, JD | 1 |
| Standaert, DG | 1 |
| Blair, RD | 1 |
| Goulet, M | 5 |
| Blanchet, PJ | 9 |
| Martel, JC | 1 |
| Piercey, MF | 1 |
| Fornai, F | 1 |
| Alessandri, MG | 1 |
| Saginario, A | 1 |
| Vaglini, F | 1 |
| Corsini, GU | 2 |
| Boucher, R | 3 |
| Gomez-Mancilla, B | 4 |
| Blanchette, P | 1 |
| Gagnon, C | 1 |
| Falardeau, P | 2 |
| DiPaolo, T | 1 |
| Shevko, GN | 1 |
| Lukhanina, EP | 1 |
| Kolomiets, BP | 1 |
| Cardoso, F | 1 |
| Jankovic, J | 1 |
| Smith, RD | 1 |
| Zhang, Z | 1 |
| Kurlan, R | 1 |
| McDermott, M | 1 |
| Gash, DM | 1 |
| Pope-Coleman, A | 1 |
| Marsden, CD | 3 |
| Grondin, R | 5 |
| Arai, N | 1 |
| Isaji, M | 1 |
| Kojima, M | 1 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
| Lopez, W | 1 |
| Jeste, DV | 1 |
| Britton, DR | 2 |
| Shiosaki, K | 2 |
| Banerji, T | 1 |
| Konitsiotis, S | 2 |
| Willis, GL | 1 |
| Armstrong, SM | 1 |
| Desimone, R | 1 |
| Fiorani, M | 1 |
| Oldfield, EH | 1 |
| Madras, BK | 1 |
| Kanda, T | 1 |
| Nakamura, J | 1 |
| Kase, H | 1 |
| Kuwana, Y | 1 |
| Verhagen, L | 1 |
| Lamers, E | 1 |
| Mohanakumar, KP | 1 |
| Muralikrishnan, D | 1 |
| Thomas, B | 1 |
| McCormack, A | 1 |
| Petzinger, G | 1 |
| Janson, AM | 1 |
| Langston, WJ | 1 |
| Treseder, SA | 1 |
| Aziz, TZ | 1 |
| Davies, L | 1 |
| Stein, J | 1 |
| France, S | 1 |
| Doucet, JP | 1 |
| Robertson, GS | 1 |
| Nestler, E | 1 |
| Ekesbo, A | 1 |
| Bangassoro, E | 1 |
| Svensson, KA | 1 |
| Tedroff, J | 1 |
| Bioulac, B | 1 |
| Petzinger, GM | 1 |
| Ivashina, E | 1 |
| Jakowec, MW | 1 |
| Jakubiak, M | 1 |
| Hill, MP | 1 |
| Peggs, D | 1 |
| Page, RD | 1 |
| Chen, S | 1 |
| Yoshida, M | 1 |
| Boyce, S | 4 |
| Rupniak, NM | 4 |
| Steventon, MJ | 2 |
| Iversen, SD | 4 |
| Taylor, JR | 1 |
| Elsworth, JD | 1 |
| Roth, RH | 1 |
| Collier, TJ | 1 |
| Sladek, JR | 1 |
| Redmond, DE | 1 |
| Watts, RL | 1 |
| Herring, CJ | 1 |
| Sweeney, KM | 1 |
| Colbassani, HJ | 1 |
| Mandir, A | 1 |
| Byrd, LD | 1 |
| Iuvone, PM | 1 |
| Steventon, M | 1 |
| Tye, SJ | 1 |
| Naruse, T | 1 |
| Miyaji, M | 1 |
| Clarke, CE | 2 |
| Sambrook, MA | 2 |
| Stahl, SM | 1 |
| Pintus, S | 1 |
| Chiueh, CC | 1 |
| Weiss, JF | 1 |
| Kopin, IJ | 1 |
| Bouchard, S | 1 |
| Lieberman, AN | 1 |
| Mitchell, IJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease[NCT03639064] | Phase 2 | 15 participants (Anticipated) | Interventional | 2020-12-01 | Recruiting | ||
| Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia and Healthy Age Matched Controls; [11C]Yohimbine and [11C]MeNER PET[NCT02578849] | 45 participants (Anticipated) | Observational | 2012-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2020 |
Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dysk | 2015 |
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Dr | 2003 |
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Mode | 2004 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Dise | 2004 |
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Clinical | 2006 |
Parkinson's disease in 1984: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dy | 1984 |
Movement disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcoholism; Amphetamines; Cocaine; Dyskinesia, Drug-In | 1993 |
DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dihydroxyphenylalanine; Dopamine Agonists; Dy | 1995 |
Movement disorders and substance abuse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcoholism; Central Nervous System Stimulants; Drug In | 1997 |
Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Drug Administration Schedule | 2001 |
The use of thalamotomy in the treatment of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dyskinesia, Drug-Induced; Fema | 1992 |
The neuronal mechanism underlying parkinsonism and dyskinesia: differential roles of the putamen and caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Cats; Caudate Nucleus; Dyskine | 1991 |
115 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Additive effects of mGluR
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridg | 2021 |
Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dyskinesia, Drug-Induced; Humans; Infl | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2020 |
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, | 2020 |
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2020 |
Effects of a combination treatment of KD5040 and
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Pr | 2017 |
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2018 |
Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Behavior, Ani | 2013 |
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; | 2014 |
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus S | 2014 |
Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Dopami | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dyskinesia, | 2014 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; | 2015 |
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 2015 |
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti | 2015 |
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholin | 2016 |
Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain Chemistry; Dopamine; Dopami | 2016 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antip | 2008 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix | 2009 |
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disea | 2009 |
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsan | 2009 |
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blood-Brain Barrier; Br | 2009 |
Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomechanical Phenomena; Chromatography, High | 2010 |
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Membrane; Dyskines | 2010 |
Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbon Radioisotopes; C | 2010 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corp | 2010 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carot | 2011 |
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bioge | 2011 |
Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colorimetry; DNA Primers; Dopamine; Dyskinesi | 2011 |
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Uptake Inhibitors; Dose- | 2002 |
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Arousal; Callithrix; Ca | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine A | 2002 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Diben | 2002 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix | 2002 |
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Resp | 2002 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, | 2003 |
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; | 2003 |
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acrylamides; Animals; Antiparkinson Agents; Dopamine A | 2003 |
Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disea | 2003 |
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2003 |
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Antiparkinson Agents | 2003 |
Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Appetite; Behavior, Animal; Blinking; Dopamin | 2003 |
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopa | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkin | 2003 |
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Caber | 2003 |
Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dopamine Agents; Dopamine Agonis | 2004 |
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; | 2005 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2005 |
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dose-Response Relationship, Drug; | 2004 |
Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blotting, Western; Brai | 2005 |
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dyskinesia, Drug | 2005 |
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dehydroepiandrosterone; | 2006 |
Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Brain; Cell Death; Corpus | 2006 |
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; | 2006 |
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; C | 2007 |
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\\ increased motor disability.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzo | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dopamine Agonist | 2007 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; | 2007 |
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl | 2007 |
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Azetidines; Behavior, A | 2007 |
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Catechols; | 2007 |
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dyskinesia, Drug-Induced; L | 2007 |
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Functional Laterali | 2008 |
Striatal histone modifications in models of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberration | 2008 |
Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Autoradiography; Corpus Stri | 1995 |
beta,beta'-Iminodipropionitrile-induced persistent dyskinetic syndrome in mice is transiently modified by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Monoamines; Cerebr | 1993 |
Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Female; Globus Pall | 1994 |
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidop | 1993 |
Participation of nucleus entopeduncularis in motor instrumental reflex and entopeduncular influences on motor thalamic nuclei in normal and MPTP-treated cats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cats; Corpus Striatum; Dopamine; Dopamine Age | 1993 |
Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Atropine; Baclofen; Clonidine; Dopamine Agent | 1993 |
Developing a stable bilateral model of parkinsonism in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, | 1993 |
Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Discrimination Learning; | 1995 |
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Chore | 1996 |
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; C | 1995 |
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamin | 1996 |
Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Catecholamines; Dopamine Agonis | 1996 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Caber | 1996 |
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopami | 1997 |
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithr | 1998 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Ag | 1998 |
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Callithrix; Disease | 1999 |
A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Availability; Body Weight; Circadi | 1999 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combina | 1999 |
D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Dopamine Agen | 2000 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; | 2000 |
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, An | 2000 |
125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Basal | 2000 |
Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2000 |
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |
Endogenous dopaminergic tone and dopamine agonist action.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; alpha-Methyltyrosine; Animals; Antiparkins | 2000 |
The role of descending basal ganglia connections to the brain stem in parkinsonian akinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Brain Mapping; Brain Stem; Dom | 1998 |
Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease | 2000 |
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine A | 2001 |
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2001 |
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Respon | 2001 |
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic alpha-Antagonists; Animals; Antiparkinson A | 2001 |
Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Animals; Apomorphine; Autoradiography; Bindin | 2002 |
Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Drug Therapy, Combination; Dyskinesia, Drug-I | 1992 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carbo | 1992 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Caudate Nucleus | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Anima | 1990 |
CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Indu | 1990 |
Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chorea; Dose-Response Relationship, Drug; Dys | 1990 |
Effect of D1 receptor stimulation in normal and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1989 |
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; D | 1989 |
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, | 1989 |
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; | 1988 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1985 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Indu | 1987 |